Latest Health News
Trump Launches Costly WHO Alternative After U.S. Withdrawal
President Trump's administration announced a 'global disease surveillance' project duplicating WHO functions at triple the cost, following U.S. exit from WHO and USAID cuts linked to 834,000 deaths. Critics note it lacks WHO's global respect and achievements like polio vaccines and Sudan ceasefire efforts.
Zimbabwe rejected a $360M U.S. health deal over data concerns.
Rare Disease Day 2026 Raises Global Awareness
Observed annually on February 28, Rare Disease Day unites people worldwide to highlight challenges for those living with rare diseases. Events emphasize research advances and need for better treatments.
It coincides with FDA innovations like the Plausible Mechanism Framework for approvals.
AlphaGenome AI Revolutionizes Rare Disease Genomics
Google DeepMind's AlphaGenome, launched January 2026, identifies regulatory genetic mutations genome-wide using AI, aiding rare disease discovery. It predicts impacts on gene expression and chromatin accessibility per a Nature study.
This boosts drug development for rare conditions.
AI Identifies Vorinostat as Rett Syndrome Treatment
Harvard's Wyss Institute used AI (nemoCAD) to find vorinostat more effective than current Rett syndrome drug trofinetide. Rett syndrome causes cognitive and physical impairments mainly in girls due to X-chromosome mutation.
Vorinostat is FDA-approved for another condition.
New Gene Therapies Advance for Cystic Fibrosis
Phase I trials show KB407 and 4D-710 gene therapies improve lung function in CF patients ineligible for modulators. Nanoparticles deliver genetic therapy to lungs, aiding CF and lung cancer.
Melatonin and probiotics show promise in CF research.
FDA Nears Approval for Achondroplasia Drug Navepegritide
Ascendis Pharma's navepegritide decision due February 28, 2026, offering weekly injections to improve growth in achondroplasia children. It provides an alternative to daily injections for body proportionality.
This targets a common form of dwarfism.
Regeneron DB-OTO Gene Therapy for Congenital Deafness
Anticipated FDA decision in early 2026 for DB-OTO, first gene therapy restoring hearing by fixing otoferlin defects. It offers one-time treatment over cochlear implants for deaf children.
This could transform outcomes for genetic hearing loss.
Rocket Pharma's Curative Therapy for Immune Disorder
Marnetegragene autotemcel (Kresaldi) decision March 28, 2026, for leukocyte adhesion deficiency-I, a fatal pediatric immune disease. It's a one-time gene therapy alternative to stem cell transplants.
Aims to prevent childhood fatalities.
Ultrasound Breakthrough Enhances Brain Cancer Chemo Delivery
WVU RNI trial shows microbubble-focused ultrasound safely opens blood-brain barrier for better glioma chemotherapy. Published in The Lancet Oncology, it improves survival vs. controls.
Enables non-invasive tumor monitoring via biomarkers.
PET/CT Tracer Predicts Rheumatoid Arthritis Treatment Response
New targeted PET/CT detects anti-TNF response in RA patients within four weeks, per Journal of Nuclear Medicine. Allows early switch for non-responders, vs. 3-6 months standard.
Supports personalized RA therapies.
Methane Converted to Hormone Therapy Drug in Breakthrough
CiQUS researchers used light and iron catalyst to turn methane into dimestrol, a non-steroidal estrogen for hormone therapy. Published in Science Advances, it enables sustainable pharma production from natural gas.
First direct synthesis from methane.
CHEO's ThinkRare AI Expands Nationally for Pediatrics
ThinkRare, world's first pediatric AI for rare diseases, launches national expansion from CHEO Research Institute. It aids diagnosis in pediatric centers.
Breakthrough announced February 27, 2026.